These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 17622837)

  • 1. Experience of indinavir/ritonavir 400/100 mg twice-daily highly active antiretroviral therapy-containing regimen in HIV-1-infected patients in Bamako, Mali: the NOGOMA Study.
    Canestri A; Cisse M; Marcelin AG; Peytavin G; Traore E; Assoumou L; Traore O; Koita V; Diallo F; Sangare AT; Sidibé MK; Calvez V; Sylla A; Katlama C; Tubiana R
    J Acquir Immune Defic Syndr; 2007 Aug; 45(4):477-9. PubMed ID: 17622837
    [No Abstract]   [Full Text] [Related]  

  • 2. Open-label study of a twice-daily indinavir 800-mg/ritonavir 200-mg regimen in HIV-infected adults failing a protease inhibitor regimen.
    Katner HP; Paar DP; Nadler JP; Jensen EH; Wilson HM; Finn TS; Petruschke RA; Zeldin RK
    J Acquir Immune Defic Syndr; 2002 Dec; 31(5):483-7. PubMed ID: 12473836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using ritonavir with indinavir in cases of virologic failure.
    TreatmentUpdate; 2001; 12(12):7. PubMed ID: 11570095
    [No Abstract]   [Full Text] [Related]  

  • 4. Open-label study of a twice-daily indinavir 800-mg/ritonavir 100-mg regimen in protease inhibitor-naive HIV-infected adults.
    Young B; Fischl MA; Wilson HM; Finn TS; Jensen EH; DiNubile MJ; Zeldin RK
    J Acquir Immune Defic Syndr; 2002 Dec; 31(5):478-82. PubMed ID: 12473835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ritonavir and indinavir one year later.
    TreatmentUpdate; 2001; 12(12):6-7. PubMed ID: 11570094
    [No Abstract]   [Full Text] [Related]  

  • 6. Health-related quality of life in HIV patients switching to twice-daily indinavir/ritonavir regimen or continuing with three-times-daily indinavir-based therapy.
    Badía X; Podzamczer D; Moral I; Roset M; Arnaiz JA; Loncà M; Casiró A; Rosón B; Gatell JM;
    Antivir Ther; 2004 Dec; 9(6):979-85. PubMed ID: 15651756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Indinavir/ritonavir-based therapy in HIV-1-infected antiretroviral therapy-naive patients: comparison of 800/100 mg and 400/100 mg twice daily.
    Konopnicki D; De Wit S; Poll B; Crommentuyn K; Huitema A; Clumeck N
    HIV Med; 2005 Jan; 6(1):1-6. PubMed ID: 15670245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experience of a combination including indinavir 400 mg plus ritonavir 200 mg twice daily in HIV-infected patients: pharmacokinetic data.
    Solas C; Petit N; Orticoni M; Durand A; Gastaut JA; Lacarelle B
    Pathol Biol (Paris); 2002 Nov; 50(9):565-7. PubMed ID: 12490421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Administration of indinavir and low-dose ritonavir (800/100 mg twice daily) with food reduces nephrotoxic peak plasma levels of indinavir.
    Aarnoutse RE; Wasmuth JC; Fätkenheuer G; Schneider K; Schmitz K; de Boo TM; Reiss P; Hekster YA; Burger DM; Rockstroh JK
    Antivir Ther; 2003 Aug; 8(4):309-14. PubMed ID: 14518700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switch from indinavir to ritonavir-indinavir regimen in patients treated with highly active antiretroviral therapy co-infected with hepatitis C is not associated with alteration of liver function tests.
    Vora S; Michon C; Junet C; Balavoine JF; Renold-Moynier C; Yerly S; Perrin L
    AIDS; 2000 Dec; 14(17):2795-7. PubMed ID: 11125903
    [No Abstract]   [Full Text] [Related]  

  • 11. First-line ritonavir/indinavir 100/800 mg twice daily plus nucleoside reverse transcriptase inhibitors in a German multicentre study: 48-week results.
    Voigt E; Wickesberg A; Wasmuth JC; Gute P; Locher L; Salzberger B; Wöhrmann A; Adam A; Weitner L; Rockstroh JK
    HIV Med; 2002 Oct; 3(4):277-82. PubMed ID: 12444946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lopinavir/ritonavir vs. indinavir/ritonavir in antiretroviral naive HIV-infected patients: immunovirological outcome and side effects.
    Bongiovanni M; Bini T; Chiesa E; Cicconi P; Adorni F; Monforte d'Arminio A
    Antiviral Res; 2004 Apr; 62(1):53-6. PubMed ID: 15026202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pilot trial of indinavir, ritonavir, didanosine, and lamivudine in a once-daily four-drug regimen for HIV infection.
    Mole L; Schmidgall D; Holodniy M
    J Acquir Immune Defic Syndr; 2001 Jul; 27(3):260-5. PubMed ID: 11464145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
    Mootsikapun P; Chetchotisakd P; Anunnatsiri S; Boonyaprawit P
    Antivir Ther; 2005; 10(8):911-6. PubMed ID: 16430196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load.
    Arnaiz JA; Mallolas J; Podzamczer D; Gerstoft J; Lundgren JD; Cahn P; Fätkenheuer G; D'Arminio-Monforte A; Casiró A; Reiss P; Burger DM; Stek M; Gatell JM;
    AIDS; 2003 Apr; 17(6):831-40. PubMed ID: 12660530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of dyslipidemias associated with either lopinavir/ritonavir- or indinavir/ritonavir-based antiretroviral therapy.
    Antoniou T; Park-Wyllie L; Boyle E
    J Acquir Immune Defic Syndr; 2004 Dec; 37(5):1666-7. PubMed ID: 15577427
    [No Abstract]   [Full Text] [Related]  

  • 17. Risk factors for ritonavir intolerance and outcome after change to indinavir.
    Casado JL; Perez-Elías MJ; Antela A; Martí-Belda P; de Lucas S; Muñoz V; Guerrero A
    AIDS; 1998 Feb; 12(3):335-6. PubMed ID: 9580044
    [No Abstract]   [Full Text] [Related]  

  • 18. Ritonavir boosted indinavir treatment as a simplified maintenance "mono"-therapy for HIV infection.
    Kahlert C; Hupfer M; Wagels T; Bueche D; Fierz W; Walker UA; Vernazza PL
    AIDS; 2004 Apr; 18(6):955-7. PubMed ID: 15060447
    [No Abstract]   [Full Text] [Related]  

  • 19. A patient's guide to protease inhibitors.
    Elperin A; Sax P
    AIDS Clin Care; 1996 Oct; 8(10):83-4. PubMed ID: 11363988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of two modalities of triple HIV therapy: probable superiority of indinavir.
    Eiros Bouza JM; Ortega M; Ortiz de Lejarazu R; Blanco R; Bachiller P; de Luis DA
    Int J Antimicrob Agents; 2004 Mar; 23(3):304-6. PubMed ID: 15164974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.